Price$35.65-0.10 (-0.28%)
2026-03-042026-06-05
Latest news
25 items- PRAllianceBernstein Launches Five New Active ETFsLineup includes one Buffered product and four Fixed Income products in AB's ETF suite NASHVILLE, Tenn., Dec. 13, 2023 /PRNewswire/ -- AllianceBernstein Holding L.P. (NYSE:AB) and AllianceBernstein L.P., a leading global investment management and research firm, announced today the launch of five active exchange-traded funds (ETFs) on the NASDAQ and New York Stock Exchange (NYSE) Arca: AB Conservative Buffer ETF (NASDAQ:BUFC), AB Tax-Aware Intermediate Municipal ETF (NYSE:TAFM), AB Tax-Aware Long Municipal ETF (NYSE:TAFL), AB Corporate Bond ETF (NASDAQ:EYEG), and AB Core Plus Bond ETF (NASDAQ:CPLS). "On the heels of crossing the $1 billion threshold in active ETF AUM, these new ETFs will prov
- SECSEC Form 10-Q filed by Eyegate Pharmaceuticals, Inc.10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- INSIDERSEC Form 4 filed by Daniels Eric Joseph4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 3 filed by new insider Daniels Eric Joseph3 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- SECEyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- PREyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development StrategySALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company's aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Company's newly revamped clinical development strategy is available in the Investors section of the Company's new website at www.kiorapharma.com. "T
- SECSEC Form D filed by Eyegate Pharmaceuticals, Inc.D - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
- INSIDERSEC Form 4: From Stephen covered exercise/tax liability with 250 shares, decreasing direct ownership by 0.36% to 68,292 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4: Mann Brenda covered exercise/tax liability with 62 shares, decreasing direct ownership by 0.41% to 15,136 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4: Romano Sarah covered exercise/tax liability with 83 shares, decreasing direct ownership by 0.36% to 23,059 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- SECEyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
- PREyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. ("Bayon") and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a ‘molecular p
- INSIDERSEC Form 4: Romano Sarah covered exercise/tax liability with 83 shares, decreasing direct ownership by 0.36% to 23,142 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4: Mann Brenda covered exercise/tax liability with 62 shares, decreasing direct ownership by 0.41% to 15,198 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4: From Stephen covered exercise/tax liability with 249 shares, decreasing direct ownership by 0.36% to 68,542 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- SECEyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
- PREyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceWALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. The presentation and archiv
- PREyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers- -Trial remains on track with topline data expected in Q4 2021- WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept ("POC") study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry e
- INSIDERSEC Form 4: From Stephen covered exercise/tax liability with 253 units of Common Stock, decreasing direct ownership by 0.37% to 68,791 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4: Romano Sarah covered exercise/tax liability with 84 units of Common Stock, decreasing direct ownership by 0.36% to 23,225 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4: Mann Brenda covered exercise/tax liability with 61 units of Common Stock, decreasing direct ownership by 0.40% to 15,260 units4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
- SECEyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Leadership Update8-K - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form D filed by Eyegate Pharmaceuticals, Inc.D - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
- 13D/GSEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
- 13D/GSEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
EYEG FAQ
8 questionsWhat does Eyegate Pharmaceuticals, Inc. do?
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop...Where does EYEG stock trade?
Eyegate Pharmaceuticals, Inc. (EYEG) is listed on NASDAQ.What sector and industry is EYEG in?
Eyegate Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Eyegate Pharmaceuticals, Inc. go public?
Eyegate Pharmaceuticals, Inc. (EYEG) completed its IPO in n/a.Does EYEG pay a dividend?
EYEG's most recent ex-dividend date was 2026-06-01 with a cash dividend of $0.14 per share. No future ex-date is on file yet.What are analysts saying about EYEG?
Eyegate Pharmaceuticals, Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $1100.00 price target on 2021-08-16. Recent price targets cluster around $1100.00.What companies are similar to EYEG?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare EYEG side-by-side with any of them on Quantisnow.How can I track EYEG on Quantisnow?
Quantisnow aggregates Eyegate Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EYEG to receive live email and push alerts on every new disclosure.